Floatz Rating
B63/100
Confidence
Indicative
Sponsor
University of Southern California
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
48High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01155258CT.gov Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors | — | Completed | — | — | — |
NCT00093782CT.gov Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Pancreatic Endocrine Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Temsirolimus (this asset) | University of Southern California | P2 | B · 63 |
| Carboplatin | ECOG-ACRIN Cancer Research Group | P2 | B |
| Everolimus | Emory University | P2 | B |
| Gefitinib | National Cancer Institute (NCI) | P2 | B |
| Ziv-Aflibercept | National Cancer Institute (NCI) | P2 | B |
| Capecitabine | Alliance for Clinical Trials in Oncology | P2 | B |
| Irinotecan | Roswell Park Cancer Institute | P2 | B |
| Regorafenib | University of Southern California | P2 | B |
| Sorafenib | National Cancer Institute (NCI) | P2 | B |
+18 more in the Pancreatic Endocrine Carcinoma cohort
Other indications for Temsirolimus
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Gliosarcoma | — | P2 | BBB · 74 |
| Adult Glioblastoma | — | P2 | BBB · 74 |
| Giant Cell Glioblastoma | — | P2 | BBB · 72 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Temsirolimus in Pancreatic Endocrine Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/temsirolimus-pancreatic-endocrine-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →